Meglumine antimoniate
From Infogalactic: the planetary knowledge core
(Redirected from Meglumine antimonate)
Systematic (IUPAC) name | |
---|---|
Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
|
|
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Identifiers | |
CAS Number | 133-51-7 |
ATC code | P01CB01 (WHO) QP51AB01 (WHO) |
PubChem | CID: 64953 |
ChemSpider | 58479 |
ChEMBL | CHEMBL239129 |
NIAID ChemDB | 008733 |
Chemical data | |
Formula | Variable |
Molecular mass | Variable |
|
|
|
|
(what is this?) (verify) |
Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
See also
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Aventis press release, 15 April 2005. (German)
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Articles with German-language external links
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs with no legal status
- Antiprotozoal agents
- Antimony compounds
- World Health Organization essential medicines
- Antiinfective agent stubs